Rodman & Renshaw Announces the Healthcare Panel Discussions Taking Place During the Rodman & Renshaw Annual Global Investment Conference at the New York Palace Hotel, September 13-15, 2010

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), a leading full service investment bank for growth companies today announced that on September 13-15, 2010, Rodman will host several expert discussions during the Rodman & Renshaw Annual Global Investment Conference.

Navigating the Changing Regulatory Landscape of Laboratory Developed Tests
Tuesday, September 14^th 2010 at 8:00 am in the Spellman Salon at the New York Palace Hotel

The US FDA plans to implement and enforce novel and existing regulations regarding laboratory developed tests. The agency held a public hearing on this topic in mid-July, 2010. Earlier this year, the FDA banned the sales of a genetic test by Pathway Genomics Corp, which was aimed at the consumer market. In parallel, the US Congress is investigating direct-to-consumer genetic testing, and is working with the FDA on new regulations. When and how will these regulations affect the genetic testing industry? How will this affect specific companies, and how will their respective management teams prepare to address this evolving regulatory landscape? Our panel, composed of a current FDA Director of CDRH/OIVD, a President of one of the largest laboratory testing associations in the US, and company representatives, will explore this subject and discuss the challenges and opportunities it presents.

Our panelists include Dr. Courtney Harper, Director of the Division of Chemistry and Toxicology Devices at the FDA, Alan Mertz, President of the American Clinical Laboratory Association, as well as senior management from Enzo Biochem, Exact Sciences, Interleukin Genetics, NeoGenomics, and Sequenom. The panel will be moderated by Elemer Piros, Ph.D., and Reni Benjamin, Ph.D., Managing Directors, Senior Biotechnology Analysts, Rodman & Renshaw.

Structural Changes in the Capital Markets and Their Impact on Emerging Life Science Companies
Tuesday, September 14^th 2010 at 1:00 pm in the Spellman Salon at the New York Palace Hotel

Have structural changes in the US capital markets inadvertently created significant hurdles to capital formation and accumulation for emerging growth companies? Our panel explores this question, its impact on various industry participants (VCs, Pharma, financial intermediaries, emerging growth life science companies) as well as, strategies for accessing capital in this challenging environment. In addition, the panel will also discuss alternatives for revitalizing the small cap public markets.

Our panelists include David Weild, founder of Capital Markets Advisory Partners and former Vice Chairman of the NASDAQ, Stephen Simes, Vice Chairman and CEO of BioSante, Ellen Lubman, Group Director, Strategic Transactions Group, Bristol-Myers Squibb, Alex Zisson, Partner, Thomas, McNerney & Partners, and Mitch Bloom, Partner and co-Chair of the Life Sciences Practice, Goodwin Proctor. The panel will be moderated by Hany Awadalla, Managing Director, Rodman & Renshaw.

A Panel Discussion on Transcatheter Valves
Tuesday, September 14^th 2010 at 3:15 pm in the Garrison Salon at the New York Palace Hotel

Transcatheter Valves are being heralded as the next "big thing” in cardiology. Will the science live up to expectations? Is the surgical community at risk of losing one of its last main domains? How does this technology stack up in this environment of greater focus on cost-effectiveness? Our panel attempts to explore these questions in an unbiased format, the impact on various industry participants, as well as, strategies for patient care moving forward.

Our panelists include experts in the field of interventional cardiology and in cardiothoracic surgery. On the cardiology side, we have Dr. Saibal Kar, Associate Professor at UCLA Geffen School of Medicine and a practicing interventionalist; and Dr. Peter Block, a practicing interventionalist at Emory University. On the surgeon side, we have Drs Allan. Stewart and Dr. Matthew Williams of Columbia University, both with extensive experience in the field of structural heart repair. The panel will be moderated by Suraj Kalia, Managing Director, Rodman & Renshaw.

As The Drug Patent Landscape Evolves, Strategic Challenges and Opportunities Develop
Wednesday, September 15^th 2010 at 8:00 am in the Spellman Salon at the New York Palace Hotel

Drug company executives and life science investors are basing decisions predicated on drug patents, FDA regulatory decisions and USPTO procedures. There are a number of changes underway that are affecting these legal foundations which will impact drug companies and investment portfolios. We will discuss some of these changes, including the FTC’s focus on authorized generic deals, pre-emption decisions and the impact on a brand and generic firm’s product liabilities, the current status of the US Supreme Court's 2007 KSR decision, and the impact that bioequivalency standards might have on the approval of biosimilars. In our panel discussion, we will review these changes and present ways in which companies and investors can either benefit or minimize their risk.

Our panelists include Michael Davitz, MD, JD, Partner at Axinn, Veltrop & Harkrider LLP, S. Peter Ludwig, Principal, Fish & Richardon, P.C. and Kurt Karst, Director, Hyman, Phelps and McNamara, P.C., co-author of the FDA Law Blog. The panel will be moderated by Michael Higgins, Managing Director, Senior Specialty Pharmaceuticals Analyst, Rodman & Renshaw.

The Rodman & Renshaw Annual Global Investment Conference will be held at the New York Palace Hotel September 12^th-15^th. Henry M. Paulson, Jr., 74^th United States Secretary of the Treasury (2006-2009), will open the conference as the keynote speaker on Monday, September 13, 2010 in a moderated interview hosted by Lawrence Kudlow, renowned free market, supply-side economist and host of CNBC's The Kudlow Report. William Isaac, former Chairman of the Federal Deposit Insurance Corporation (FDIC) and author of the 2010 book Senseless Panic: How Washington Failed America, will also be a special guest speaker at the conference on Tuesday, September 14^th 2010 at 5:30 PM.

Following Mr. Paulson's opening program, more than 550 public and private companies from around the world are expected to present to an audience of over 3,500 attendees. The conference will also feature tracks dedicated to Healthcare, China, Metals & Mining, Energy, Technology, Cleantech, and REITs. To register for the conference, please visit: http://www.rodm.com/conferences

About Rodman & Renshaw Capital Group, Inc.

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM) is a holding company with a number of direct and indirect subsidiaries, including Rodman & Renshaw, LLC.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of deal volume of PIPE and RD financing transactions completed every year since 2005.

For more information visit Rodman & Renshaw on the Internet at www.rodm.com.

MEMBER FINRA, SIPC